文献速递贫血与红细胞疾病

尼日利亚镰状细胞贫血年长儿童重度急性营养不良管理的可行性试验

Feasibility trial for the management of severe acute malnutrition in older children with sickle cell anemia in Nigeria.
PubMed 文献 · Blood Adv · 2023-01-01

在尼日利亚开展多中心随机对照可行性试验,评估5至12岁镰状细胞贫血合并重度急性营养不良(体重指数z评分<-3.0)患儿接受即用型治疗食品(RUTF)联合或不联合中剂量羟基脲(20 mg/kg/天)治疗的可行性与安全性。共筛查3190名儿童,111名符合条件者中入组110名;12周内无退出或失访,1例因无关原因死亡,羟基脲依从性94%、RUTF依从性100%,未发生再喂养综合征或羟基脲相关骨髓抑制,体重指数z评分平均变化0.49(标准差=0.53),39%的参与者体重指数z评分改善至≥-3.0。

要点

  • 5至12岁镰状细胞贫血合并重度急性营养不良患儿中,RUTF联合或不联合羟基脲的12周门诊治疗可行且安全。
  • 羟基脲依从性94%(基于药片计数),RUTF依从性100%(基于空袋回收数),无再喂养综合征或羟基脲相关骨髓抑制。
  • 体重指数z评分平均变化0.49(标准差=0.53),39%的参与者改善至≥-3.0;但RUTF与家庭成员和社区成员分享可能混杂营养不良治疗反应。

核心结论

  • 在资源有限环境下,对5至12岁镰状细胞贫血合并重度急性营养不良患儿进行门诊治疗具有可行性、安全性和潜力。

研究设计与样本

  • 多中心、随机对照可行性试验,纳入5至12岁镰状细胞贫血合并单纯性重度急性营养不良(体重指数z评分<-3.0)儿童,随机分配接受补充即用型治疗食品(RUTF)联合或不联合中剂量羟基脲(20 mg/kg/天)治疗。
  • 6个月入组期内筛查3190名5至12岁镰状细胞贫血儿童,111名符合条件者中入组110名。

主要发现

  • 12周试验期间无参与者退出或失访,1例参与者因无关原因死亡。
  • 羟基脲依从性94%(基于药片计数),RUTF依从性100%(基于空袋回收数)。
  • 未发生再喂养综合征事件或羟基脲相关骨髓抑制。
  • 试验结束时,体重指数z评分平均变化为0.49(标准差=0.53),39%的参与者体重指数z评分改善至≥-3.0。

关键数值与推荐

  • 单纯性重度急性营养不良定义为体重指数z评分<-3.0。
  • 羟基脲剂量为20 mg/kg/天。
  • RUTF与家庭成员和社区成员分享可能混杂营养不良治疗反应。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • RUTF与家庭成员和社区成员分享可能混杂营养不良治疗反应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Children with sickle cell anemia (SCA) living in Nigeria are at an increased risk of malnutrition, which contributes to increased morbidity and mortality. However, evidence-based guidelines for managing malnutrition in children with SCA are lacking. To address this gap, we conducted a multicenter, randomized controlled feasibility trial to assess the feasibility and safety of treating children with SCA aged from 5 to 12 years and having uncomplicated severe acute malnutrition (body mass index z score of <-3.0). Children with SCA and uncomplicated severe acute malnutrition were randomly allocated to receive supplemental ready-to-use therapeutic food (RUTF) with or without moderate-dose hydroxyurea therapy (20 mg/kg per day). Over a 6-month enrollment period, 3190 children aged from 5 to 12 years with SCA were evaluated for eligibility, and 110 of 111 children who were eligible were enrolled. During the 12-week trial, no participants withdrew or missed visits. One participant died of unrelated causes. Adherence was high for hydroxyurea (94%, based on pill counts) and RUTF (100%, based on the number of empty sachets returned). No refeeding syndrome event or hydroxyurea-related myelosuppression occurred. At the end of the trial, the mean change in body mass index z score was 0.49 (standard deviation = 0.53), and 39% of participants improved their body mass index z score to ≥-3.0. Our findings demonstrate the feasibility, safety, and potential of outpatient treatment for uncomplicated severe acute malnutrition in children with SCA aged from 5 to 12 years in a low-resource setting. However, RUTF sharing with household and community members potentially confounded the response to malnutrition treatment. This trial was registered at clinicaltrials.gov as #NCT03634488.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Abdullahi SU, Gambo S, Murtala HA, et al. Feasibility trial for the management of severe acute malnutrition in older children with sickle cell anemia in Nigeria. Blood Adv. 2023. PMID: 37428866. doi:10.1182/bloodadvances.2023010789

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。